Green Cross Says It Secured Korea's Largest-ever Agreement For Finished Product Export
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean vaccine producer Green Cross said it signed a three-year $480 million memorandum of understanding with ASD Healthcare of the U.S. to export intravenous immunoglobulin and hemophilia type A treatment GreenGene-F to the U.S, which would be the country's largest-ever agreement for finished drugs